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Abstract 
Background: Intraoperative intravascular volume expansion with hydroxyethyl starch-based colloids is thought to 
be associated with an increased risk of post-craniotomy hemorrhage. Evidence for this association is limited. Associa-
tions between resuscitation with hydroxyethyl starch and risk of repeat craniotomy for hematoma evacuation were 
examined.
Methods: Using a retrospective cohort of neurosurgical patients at Duke University Medical Center between March 
2005 and March 2012, patient characteristics were compared between those who developed post-craniotomy hem-
orrhage and those who did not.
Results: A total of 4,109 craniotomy procedures were analyzed with 61 patients having repeat craniotomy for post-
operative hemorrhage (1.5%). The rate of reoperation in the group receiving 6% High Molecular Weight Hydroxyethyl 
Starch (Hextend®) was 2.6 vs. 1.3% for patients that did not receive hetastarch (P = 0.13). The reoperation rate for those 
receiving 6% hydroxyethyl Starch 130/0.4 (Voluven®) was 1.4 vs. 1.6% in patients not receiving Voluven (P = 0.85).
Conclusions: In this retrospective cohort, intra-operative hydroxyethyl starch was not associated with an increased 
risk of post-craniotomy hemorrhage.
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Background
Hydroxyethyl starch (HES) based colloids have gained 
popularity in clinical anesthesia practice due to their 
effective intravascular volume expansion (Kozek-Lan-
genecker 2005). Recently, there have been studies warn-
ing providers to limit the volume infused because of 
concerns for platelet dysfunction and increased bleed-
ing (Kozek-Langenecker 2005; Westphal et  al. 2009; 
Myburgh and Mythen 2013; Hartog et  al. 2011), based 
on in  vitro coagulation abnormalities (Avorn et  al. 
2003; Wilkes et  al. 2001; Strauss 1981). For example, in 
a porcine model of liver trauma HES has been shown 
to provoke uncontrolled hemorrhage (Zaar et  al. 2009). 
Similarly, in a small prospective randomized trial of 40 
patients undergoing major surgery the impact of HES on 
coagulation was apparent, as HES reduced clot strength 
and increased perioperative hemorrhage by more than 
50% (Rasmussen et al. 2014). Even when used at less than 
the recommended maximum dose, HES use has been 
associated with increased postoperative bleeding and 
transfusion in patients undergoing heart surgery requir-
ing cardiac bypass (Avorn et al. 2003; Wilkes et al. 2001). 
There have also have been small studies associating the 
use of HES with intracranial bleeding and coagulopathy 
in the setting of subarachnoid hemorrhage (Damon et al. 
1987; Knutson et al. 2000). The mechanisms causing this 
acquired coagulopathy include qualitative platelet dys-
function, decreases in Factor VIII/von Willebrand’s fac-
tor complexes (sometimes referred to as “Acquired von 
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Willebrand’s disease-Type 1”), and qualitative disruption 
of fibrin clots (Trumble et  al. 1995; Jonville-Bera et  al. 
2001).
The cranium is a closed compartment where small vol-
umes of blood can cause clinical, even life-threatening, 
symptoms. Previous studies show that 1–2% of post-cra-
niotomy patients have symptomatic hemorrhage requir-
ing intervention (Treib et al. 1999; Field et al. 2001). We 
aimed to determine whether intraoperative HES admin-
istration, compared with no HES, was associated with 
post-craniotomy hemorrhage requiring reoperation in a 
large retrospective cohort.
Results
Out of a total of 4,109 craniotomy procedures, 61 patients 
underwent repeat craniotomy for post-operative hem-
orrhage. The overall reoperation rate for postoperative 
intracranial hemorrhage was 1.5%. The mean ± SD esti-
mated blood loss was 331 ± 415 mL (Range 5–7,200 mL) 
and the average volume of crystalloid administered was 
2,704 ± 1,863 mL (Range 75–20,200 mL). HES was used 
in 334 operations (8.1% of cases), including Hextend® 
use in 190 cases (5.0%) and Voluven® in 144 cases (2.8%) 
(Figure  1). The average volume of Hextend® adminis-
tered was 635 ± 286 mL (Range 100–1,600 mL) and the 
average volume of Voluven® was 725 ±  350  mL (Range 
250–2,000 mL).
Between March 2005 and March 2010, when Hextend® 
was in use, a total of 2,883 craniotomies were performed. 
Of these procedures, 41 (1.4%) patients had a repeat 
craniotomy for post-operative hemorrhage. The post-
operative hemorrhage group was more likely to be male, 
to have a tumor or trauma as the reason for craniotomy, 
and to have received a greater volume of crystalloid and 
packed red blood cells compared with those who did not 
have a post-operative hemorrhage (Table 1). During this 
time, there was no significant difference in the propor-
tion of patients who received Hextend® among those 
who had a post-operative hemorrhage and those who did 
not (Table 1).
Between March 2010 and March 2012, when Voluven® 
was in use, a total of 1,287 craniotomies were performed. 
Of these procedures 20 (1.6%) patients had a repeat cra-
niotomy for post-operative hemorrhage. The post-oper-
ative hemorrhage group was more likely to be older, to 
have a greater ASA Grade, and to have received packed 
red blood cells, fresh frozen plasma, and platelets com-
pared to those who did not have a post-operative hem-
orrhage. During this time, there was no difference in the 
proportion of patients who received Voluven® among 
those who had a post-operative hemorrhage requir-
ing repeat craniotomy and those who did not (Table 2). 
Reoperation occurred most commonly on post-operative 
day 1 (Figure 2).
Discussion
Intraoperative HES use was not associated with reop-
eration for intracranial bleeding after craniotomy in our 
cohort. Similarly, Jian and colleagues found that HES was 
not a risk factor for post-craniotomy intracranial hema-
toma requiring surgery (Jian et  al. 2014). The rate of 
reoperation for post-craniotomy intracranial hemorrhage 
in our cohort is similar to previously published rates 
(Field et al. 2001). Reoperation occurred most commonly 
on post-operative day 1, consistent with previous studies 
of post-operative hematoma evacuations (Jian et al. 2014; 
Kelly et al. 2011).
Our study has limitations. This is a secondary analysis 
performed using observational data collected at a single 
institution. We did not perform multivariate analyses to 
adjust for confounding variables. We also did not quanti-
tatively examine dose–response between HES and blood 
loss because of the limited accuracy of retrospective HES 
dose and estimated blood loss data. We focused on repeat 
craniotomy for hemorrhage because it was an unambigu-
ous endpoint. The study is underpowered to detect an 
increase in repeat craniotomies for post-operative hema-
toma in those exposed to HES, although our data indicate 
that the effect size is quite small. Our data may be help-
ful for any investigators planning prospective studies of 
HES in craniotomy patients. Based on our data, a future 
prospective study investigating the use of HES in crani-
otomy would need a sample size of 5,790 patients to have 
80% power to detect an increase in repeat craniotomies 
for post-operative hematoma from 1.4% (HES group) to 
2.1% (No-HES group) using a two-group Chi square test 
with a 0.05 two-sided significance level. This effect size is 
an odds ratio of 1.511.
Figure 1 Comparison of reoperation rates (for postcraniotomy hem-
orrhage) for patients who did or did not receive HES products.
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Conclusions
In conclusion, these data did not demonstrate an associa-
tion between HES use during craniotomy and post-crani-
otomy hemorrhage. Whether low-volume intraoperative 
HES bolus dosing has adequate safety requires further 
study.
Methods
After IRB approval was obtained, all craniotomy proce-
dures at Duke University Medical Center between March 
2005 and March 2012 were retrospectively reviewed 
using Duke Enterprise Data Unified Content Explorer 
(DEDUCE) and the electronic anesthesia records (Inno-
vian, Drager, Telford, PA, USA). Patients undergoing re-
operation within 30  days for intracranial hemorrhage 
were identified. If the operative note from the second 
operation indicated that the repeat craniotomy was to 
treat intracranial hemorrhage, such patients were placed 
in “Repeat Craniotomy for Postoperative Hemorrhage” 
group. All other craniotomy patients were placed in the 
“No Repeat Craniotomy for Postoperative Hemorrhage” 
group. Demographic information was obtained as well as 
relevant risk factors for post-operative bleeding including 
preoperative coagulation parameters, estimated blood 
loss, and operative site. HES use and other intraoperative 
fluids were identified from electronic anesthesia records 
associated with these cases. Of note, the attending neu-
rosurgeons performing the majority of craniotomies as 
well as the intravenous fluids (normal saline and Ringer’s 
lactate) administered were consistent over the period of 
the study.
In March 2010, there was an institutional switch 
from Hextend® (HES 6%/200/0.5) to Voluven® (HES 
6%/130/0.4). Our data set includes both HES products 
and analyzes data for each product separately.
Statistical analysis
Means and standard deviations were reported for con-
tinuous variables. Medians were reported for skewed 
distributions of continuous variables. Proportions were 
reported for categorical data. Characteristics were com-
pared using a 2 sample t test or Pearson’s Chi square 
Table 1 Demographic and clinical characteristics of the March 2005–March 2010 Cohort
* Plasmanate is a purified plasma derivative consisting predominantly of human albumin.
N = 2,801 N = 41 p value
No repeat craniotomy for  
post-operative hemorrhage
Repeat craniotomy for  
post-operative hemorrhage
Mean age, years (SD) 51.0 (16.0) 54.6 (15.5) 0.7
Male, n (%) 1,322 (47.4) 25 (62.5) 0.06
ASA grades 1–2, n (%) 1,236 (46.9) 20 (50.0) 0.82
ASA grades 3–5, n (%) 1,152 (53.1) 20 (50.0) 0.82
E Cases, n (%) 328 (12.1) 2 (5.0) 0.18
Tumor, n (%) 1,393 (49.7) 32 (80.0) <0.0001
Vascular, n (%) 305 (10.9) 6 (15.0) 0.23
Trauma/other, n (%) 1,104 (39.5) 2 (5.0) <0.0001
Baseline coagulopathy, n (%) 58 (2.1) 1 (2.5) 0.85
Mean EBL, mL (SD) 279.1 (391.9) 540.2 (1,176.2) 0.16
Mean operation length, min (SD) 229.2 (120.6) 226.3 (159.5) 0.15
Mean crystalloid volume, mL (SD) 2,694.9 (1909.5) 3,620.7 (2,351.1) <0.0001
Received plasmanate*, n (%) 420 (14.7) 8 (19.5) 0.38
Mean plasmanate* volume, mL (SD) 529.7 (352.9) 750 (353.6) 0.21
Received hextend, n (%) 185 (6.6) 5 (12.5) 0.15
Mean hextend volume, mL (SD) 635.4 (286.9) 650 (335.4) 0.89
Received PRBCs, n (%) 194 (6.9) 3 (7.5) 0.89
Mean PRBCs volume, mL (SD) 877.5 (901.5) 2,450 (1,603.9) 0.003
Received FFP, n (%) 82 (2.9) 3 (7.5) 0.09
Mean FFP volume, mL (SD) 660.2 (603.0) 1,227 (1,050.7) 0.12
Received platelets, n (%) 91 (3.2) 1 (2.5) 0.77
Mean platelets volume, mL (SD) 353.0 (208.6) 563 (–) –
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Table 2 Demographics and clinical characteristics of the March 2010 and March 2012 cohort
* Plasmanate is a purified plasma derivative consisting predominantly of human albumin.
N = 1,247 N = 20 p value
No repeat craniotomy for  
post-operative hemorrhage
Repeat craniotomy for  
post-operative hemorrhage
Mean age, years (SD) 51.6 (16.3) 61.8 (14.8) 0.007
Male, n (%) 632 (50.7) 9 (45.0) 0.61
ASA grades 1–2, n (%) 488 (39.1) 2 (10.0) 0.008
ASA grades 3–5, n (%) 734 (58.9) 18 (90.0) 0.008
E Cases, n (%) 112 (9.0) 1 (5.0) 0.53
Tumor, n (%) 784 (62.9) 13 (65.0) 0.72
Vascular, n (%) 288 (23.1) 3 (15.0) 0.39
Trauma/other, n (%) 175 (14.0) 4 (20.0) 0.45
Baseline coagulopathy, n (%) 15 (1.2) 0 (0) 0.62
Mean EBL, mL (SD) 297.5 (345.2) 236.1 (157.7) 0.11
Mean operation length, min (SD) 212.1 (109.9) 197.7 (138.5) 0.65
Mean crystalloid volume, mL (SD) 2,390.5 (1,482.8) 2,683.8 (1,494.2) 0.39
Received plasmanate*, n (%) 202 (16.2) 2 (10.0) 0.45
Mean plasmanate* volume, mL (SD) 510.4 (288.8) 625 (176.8) 0.53
Received voluven, n (%) 142 (11.4) 2 (10.0) 0.85
Mean voluven volume, mL (SD) 664.4 (287.7) 750 (353.6) 0.67
Received PRBCs, n (%) 72 (5.8) 3 (15.0) 0.08
Mean PRBCs volume, mL (SD) 832.2 (893.4) 350 (0) <0.001
Received FFP, n (%) 39 (3.1) 3 (15.0) 0.003
Mean FFP volume, mL (SD) 583.3 (605.1) 539.67 (68.7) 0.67
Received platelets, n (%) 38 (3.1) 2 (10.0) 0.08
Mean platelets volume, mL (SD) 360.1 (226.7) 249 (69.3) 0.5
Figure 2 Timeline indicating when (post-operative day) patients returned for repeat craniotomy for hemorrhage.
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test. All tests of significance were two-tailed and p values 
<0.05 were considered significant. The analysis was per-
formed using SAS 9.2 (SAS, Cary, North Carolina).
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